Journal of Thrombosis and Thrombolysis

Article	Citations
Second wave of the COVID-19 pandemic: D-dimer levels are not so high anymore	64
Management of warfarin-associated intracerebral hemorrhage before and after implementation of an order set and prospective pharmacist order verification	42
Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid	41
Post-thrombolytic coagulopathy and complications in patients with pulmonary embolism treated with fixed-dose systemic alteplase	40
Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism	40
Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series	38
Meta-analysis of restrictive versus liberal blood transfusion among patients with coronary artery disease	32
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity	31
The outcomes of three-factor prothrombin complex concentrate (3F-PCC) in warfarin anticoagulation reversal: a prospective, single-arm, open-label, multicentre study	31
The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China	26
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery	25
Inhibitory effects of amniotic fluid on the activated protein C anticoagulation system in maternal plasma	25
Different patterns of white matter lesions among patent foramen ovale, atherosclerotic cerebral small vessel disease and cerebral venous thrombosis	23
The clot thickens—enhanced integration of stroke and thrombosis training	22
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	22
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection	21
Endothelial progenitor cells overexpressing platelet derived growth factor-D facilitate deep vein thrombosis resolution	20
Evaluating the safety and efficacy of intravenous thrombolysis for acute ischemic stroke patients with a history of intracerebral hemorrhage: a systematic review and meta-analysis	19
ICODE: the international COVID-19 thrombosis biomarkers colloquium—novel soluble biomarkers: circulating cell-free nucleic acids and other molecules	18
Initial assessment of α-synuclein structure in platelets	18
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	17
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography	17
Prescribing of anticoagulation for atrial fibrillation in primary care	17
Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial	16
Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson’s syndrome	16

Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation	16
Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases	16
Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria	16
Uncertainties about platelet function and genetic testing for guiding dual antiplatelet therapy in percutaneous coronary intervention	16
Safety and efficacy of catheter-directed therapy versus anticoagulation alone in a higher-risk acute pulmonary embolism population	15
Decreased pulmonary artery distensibility as a marker for severity in acute pulmonary embolism patients undergoing ECG-gated CTPA	15
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis	15
Thrombectomy for ischemic stroke with large vessel occlusion and concomitant subarachnoid hemorrhage	14
Conservative treatment vs thrombus removal for Iliofemoral vein thrombosis in patients with congenital abnormalities of the inferior vena cava: a case report and systematic review of the literature	14
Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation	14
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials	14
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia	14
Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement	14
Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure	13
Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score	13
Incidence of thrombotic complications in COVID-19	13
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population	13
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction	13
Prevalence and consequences of empiric anticoagulation for venous thromboembolism in patients hospitalized for COVID-19: a cautionary tale	13
Barriers and motivators to national board certification as a certified anticoagulation care provider	13
Roles of factor Xa beyond coagulation	12
The role of β-catenin in pulmonary artery endothelial-mesenchymal transformation in rats with chronic thromboembolic pulmonary hypertension	12
Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease	12
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis	12
Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients	12
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study	12
Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)	12
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database	12
Correction to: Cardiomyocyte microvesicles: proinflammatory mediators after myocardial ischemia?	11
Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma	11
Analysis of changes in the expression pattern of miR-326 and miR-145 during storage of platelet concentrate in blood bank condition and its relationship with some markers of platelet quality	11
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid	11
Global coagulation assays in hypercoagulable states	11
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19	11
Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event	11
Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 d	11
Guest editors’ introduction	11
Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes	10
Atypical late diagnosis of Noonan syndrome revealed by bleedings due to platelet dysfunction	10
Management of bone marrow biopsy related bleeding risks: a retrospective observational study	10
REPLY to “Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	10
Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation	10
COVID 19 infection associated with thrombotic thrombocytopenic purpura	10
Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention	10
Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation	10
Sickle cell disease related chronic thromboembolic pulmonary hypertension: challenging clinical scenario	9
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors	9
COVID-19 risk index (CRI): a simple and validated emergency department risk score that predicts mortality and the need for mechanical ventilation	9
Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series	9
Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status	9

Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)	9
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage	9
Increased incidence of massive hemorrhage at uncommon sites after initiation of systemic anticoagulation in critically ill patients with coronavirus disease 2019 (COVID-19) infection	9
Contemporary use of ventilation-perfusion imaging for pulmonary embolism diagnosis	9
Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients	9
Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics	9
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate	9
Utilization of D-dimer assay, CT angiography, and the incidence of pulmonary embolism in the hospital district of Helsinki and Uusimaa (2011–2017)	8
Incremental cost of venous thromboembolism in trauma patients with contraindications to prophylactic anticoagulation: a prospective economic study	8
Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall	8
Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19	8
Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study	8
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	8
Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma	8
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature	8
Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012)	8
Confirmation of the utility of the Wells’ Score for pulmonary embolism in patients with sickle cell disease	8
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry	8
Risk of recurrent venous thromboembolism and bleeding in patients with interstitial lung disease: a cohort study	8
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians	8
Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment	7
Recurrent hematuria and painful necrotic purpura induced by acquired Protein S deficiency associated with monoclonal immunoglobulin	7
Clinical outcomes of very elderly patients treated with ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism: a systematic review	7
Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors	7
Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity	7
Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center	7
Immature platelets in patients with Covid-19: association with disease severity	7
Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?	7
The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study	7
Prothrombinase: the paradigm for membrane bound enzyme complexes; a memoir	7
International COVID-19 biomarkers colloquium	7
Stroke and presence of patent foramen ovale in sickle cell disease	7
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor	7
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis	6
A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer	6
Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series	6
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis	6
Vitamin D levels and C-reactive protein/albumin ratio in pregnant women with cerebral venous sinus thrombosis	6
Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA	6
Overexpression of miR-1298 attenuates myocardial ischemia–reperfusion injury by targeting PP2A	6
Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study	6
Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review	6
Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells	6
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy	6
Small lipid core burden index in patients with stable angina pectoris is also associated with microvascular dysfunction: Insights from intracoronary electrocardiogram	6
Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves	6
Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia	6
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics	6
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?	6
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism	6
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients	6
Acute limb ischemia in a patient with Covid-19 pneumonia: a case report	6
A comprehensive review of vascular complications in COVID-19	6
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients	6
Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation pati	6
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies	5
Hospitalization for venous thromboembolic disease management: a 10 years Registry in Buenos Aires, Argentina	5
Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism	5
Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI	5
Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody	5
Neurological manifestations of thrombotic microangiopathy syndromes in adult patients	5
Efficacy of a hypolipid diet in patients with primary antiphospholipid syndrome with dyslipidemia: a prospective study	5
Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals	5
Circ_0003204 knockdown protects endothelial cells against oxidized low-density lipoprotein-induced injuries by targeting the miR-491-5p-ICAM1 pathway	5
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS	5
Tissue factor: a neglected role in cancer biology	5
Screening for venous thromboembolism in patients with COVID-19	5
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia	5
Adverse consequences of immediate thrombolysis-related complications: a multi-centre registry-based cohort study of acute stroke	5
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists	5
A rare case of non-traumatic spinal epidural hematoma in lumbar region associated with apixaban therapy	5
Safety of intravenous thrombolysis in stroke of unknown time of onset: A systematic review and meta-analysis	5
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series	5
U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients	5
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study	4
Association of acidosis with coagulopathy and transfusion requirements in liver transplantation	4
Answer to “REPLY to Association between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	4
ST-segment elevation in patients with COVID-19: a systematic review	4
Stroke risk factors and outcomes among hospitalized women with atrial fibrillation	4
SUPPORT‐AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF	4

Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection	4
One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic	4
Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens	4
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis	4
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone	4
Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross‐sectional study	4
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry	4
Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation	4
Impact of thrombus burden on long-term clinical outcomes in patients with either anterior or non-anterior ST-segment elevation myocardial infarction	4
Biomarkers associated with coronary high-risk plaques	4
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality	4
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE tr	4
Potent platelet inhibition with peri-procedural tirofiban may attenuate progression of atherosclerosis in patients with acute coronary syndromes	4
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer	4
Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry)	4
The use of recombinant tissue plasminogen activator in in acute ischemic stroke is associated with increased level of BDNF	4
Transient endothelial injury and release of lupus anticoagulant in COVID-19	4
Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review	4
Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice	4
Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial	4
Development and validation of a prediction model of catheter-related thrombosis in patients with cancer undergoing chemotherapy based on ultrasonography results and clinical information	4
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison	4
Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome	4
Major bleeding complications in critically ill patients with COVID-19 pneumonia	4
Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome	4
Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic	4
Nitric oxide acute kidney injury (NO-AKI) pilot trial	4
Heparin-induced thrombocytopenia in extra-corporeal membrane oxygenation: epidemiology, outcomes, and diagnostic challenges	4
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting	4
Inpatient Management of Pulmonary Embolism: Clinical Characteristics and Mortality in a High-Volume Tertiary Care Center	4
Fibrinspecific liposomes as a potential method of delivery of the thrombolytic preparation streptokinase	4
Acute coronary syndrome in patients with hemophilia: a delicate balancing act	4
Evaluation of heparin infusion rates in patients with intravenous drug misuse	4
Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin	4
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study—Reply to comment from Muzaffar et al.	4
Efficacy of interatrial shunt devices: an opening window to acute pulmonary hypertensive crisis and chronic pulmonary arterial hypertension	4